JWJackie Wong

Jackie Wong

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jackie Wong has a total of 100 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Lipoprotein(a) and Its Role in Peripheral Arterial Disease: A Narrative Review

    by Bibombe Mwipatayi, James Dodd, Amirul Hakim Ahmad Bazlee, Gabrielle Stratford, Bernadette Lee, Trevor Mori, Gerald Watts, Elizabeth Armari, Jacqueline Wong, Markus P Schlaich

    Lipoprotein (a) (Lp[a]) is an independent risk factor for cardiovascular disease (CVD). Structurally like low-density lipoprotein, Lp(a) is distinguished by the covalent attachment of apolipoprotein(a) to apolipoprotein B-100. Although its physiological role remains incompletely understood, evidence suggests that Lp(a) may facilitate wound healing and inhibit cancer growth and metastasis. In contrast, Lp(a) exhibits proatherogenic properties; it transports proinflammatory oxidized phospholipids, induces the secretion of proinflammatory cytokines, increases endothelial permeability, promotes smooth muscle cell migration and proliferation, and upregulates adhesion molecules that facilitate monocyte recruitment and retention. In addition, Lp(a) exerts prothrombotic activity by enhancing platelet aggregation, suppressing plasminogen activation, and inhibiting fibrinolysis. Although its clinical relevance in CVD is well established, the role of Lp(a) in peripheral arterial disease (PAD) remains unclear. This narrative review aimed to synthesize and critically examine the current evidence on the biological role of Lp(a) in PAD pathogenesis and identify knowledge gaps in PAD-specific outcomes. This review summarizes the epidemiology, pathophysiology, and management of elevated Lp(a) levels in patients with PAD and examines their association with post-treatment clinical outcomes. Elevated Lp(a) levels are associated with an increased PAD incidence and a higher risk of restenosis post-revascularization. Understanding the mechanisms by which Lp(a) contributes to PAD pathogenesis is essential for developing effective targeted therapeutic approaches and improving the identification and management of high-risk patients.


  • Open Access

    Frail patients having vascular surgery during the early COVID‐19 pandemic experienced high rates of adverse perioperative events and amputation

    by Australian And New Zealand Vascular Trial Network (Anzvtn), Sarah J. Aitken, Bernard Allard, Nishath Altaf, Noel Atkinson, Omar Aziz, Ruth Battersby, Ruth Benson, Jennifer L. Chambers, Gabriella Charlton, et al.

    Background Frailty predicts adverse perioperative outcomes and increased mortality in patients having vascular surgery. Frailty assessment is a potential tool to inform resource allocation, and shared decision-making about vascular surgery in the resource constrained COVID-19 pandemic environment. This cohort study describes the prevalence of frailty in patients having vascular surgery and the association between frailty, mortality and perioperative outcomes. Methods The COVID-19 Vascular Service in Australia (COVER-AU) prospective cohort study evaluates 30-day and six-month outcomes for consecutive patients having vascular surgery in 11 Australian vascular units, March-July 2020. The primary outcome was mortality, with secondary outcomes procedure-related outcomes and hospital utilization. Frailty was assessed using the nine-point visual Clinical Frailty Score, scores of 5 or more considered frail. Results Of the 917 patients enrolled, 203 were frail (22.1%). The 30 day and 6 month mortality was 2.0% (n = 20) and 5.9% (n = 35) respectively with no significant difference between frail and non-frail patients (OR 1.68, 95%CI 0.79-3.54). However, frail patients stayed longer in hospital, had more perioperative complications, and were more likely to be readmitted or have a reoperation when compared to non-frail patients. At 6 months, frail patients had twice the odds of major amputation compared to non-frail patients, after adjustment (OR 2.01; 95% CI 1.17-3.78), driven by a high rate of amputation during the period of reduced surgical activity. Conclusion Our findings highlight that older, frail patients, experience potentially preventable adverse outcomes and there is a need for targeted interventions to optimize care, especially in times of healthcare stress.


  • Excluder Stent Graft-Related Outcomes in Patients with Aortic Neck Anatomy Outside of Instructions For Use (IFU) within the Global Registry for Endovascular Aortic Treatment (GREAT): Mid-term Follow-Up Results

    by Ian P Barry, Mitchell Barns, Eric Verhoeven, Jackie Wong, Steven Dubenec, Jan Mm Heyligers, Ross Milner, William P Shutze, Paul Bachoo, Philip Vlaskovky, et al.


  • Sex-Related Outcomes After Endovascular Aneurysm Repair Within the Global Registry for Endovascular Aortic Treatment

    by Bibombe P. Mwipatayi, Tahmina Anwari, Jackie Wong, Eric Verhoeven, Steven Dubenec, Jan M. Heyligers, Ross Milner, Chiara Mascoli, Mauro Gargiulo, William P. Shutze


  • Open Access

    Multicentre Covariate Adjustment Analysis of Short-Term and 5-Year Outcomes after Endovascular Repair according to Sex

    by Bibombe P. Mwipatayi, Rebekah L.W Tan, Joseph Faraj, Ali Daneshmand, Olufemi Oshin, Nishath Altaf, Shannon D. Thomas, Patrik J Tosenovsky, Jackie Wong, Vikram Vijayan, et al.

    Background. Several studies have reported worse outcomes in women compared to men after endovascular aneurysm repair (EVAR). This study aimed to evaluate sex-specific short-term and 5-year outcomes after EVAR. Methods. A total of 409 consecutive patients underwent elective EVAR from 2004 to 2017 at two tertiary hospitals in Western Australia. Baseline, intraoperative, and postoperative variables were examined retrospectively according to sex. The primary outcome was 30-day mortality (death within 30 days after EVAR). Secondary outcomes were 30-day composite endpoint, length of stay after EVAR, 5-year survival, freedom from reintervention, residual aneurysm size after EVAR, and major adverse event rate at 5-year follow-up. Results. A cohort of 409 patients, comprising 57 women (14%) and 352 men (86%), was analysed. Female patients were older (median age, 76.8 versus 73.5 years, ). Male patients were more likely to be past smokers (40.9% versus 22.8%, ) and have a history of coronary artery bypass grafting (11.2% versus 3.5%, ) and malignancy (24.1% versus 10.5%, ). No difference in 30-day mortality or composite endpoints was demonstrated for female patients compared with male patients (3.5% versus 0.3%, and 31.6% versus 27.8%, , respectively). The Kaplan–Meier curves demonstrated similar 5-year mortality outcomes amongst male and female patients (). Long-term survival analysis adjusting for covariates demonstrated no significant difference in long-term mortality, composite endpoints, and reintervention rate between sexes. Conclusion. This study found no significant differences in 30-day and 5-year outcomes between female and male patients treated with EVAR, implying that EVAR remains a safe treatment choice for female patients.

  • Multivariable Analysis of Patients With Severe Persistent Postprocedural Hypotension After Carotid Artery Stenting

    by Olufemi Oshin, Ramon Varcoe, Jackie Wong, Sally Burrows, Nishath Altaf, Markus Schlaich, Rukshen Weerasooriya, William Gray, Koen Deloose, Iris Baumgartner, et al.

    Purpose: To assess the incidence and predictors of severe, persistent postprocedural hypotension (PPH) after carotid artery stenting (CAS). Materials and Methods: A total of 146 patients (mean age 72.8 years; 104 men) who underwent 160 CAS procedures using a standardized protocol at 3 vascular centers were retrospectively analyzed. The primary endpoint was postprocedural hypotension, defined as a reduction in systolic blood pressure (SBP) >40 mm Hg from baseline or an SBP of 1 hour after CAS. Potential prognostic factors for postprocedural hypotension were identified and subjected to logistic regression analyses; outcomes are presented as the odds ratios (ORs) with 95% confidence intervals (CIs). Results: PPH developed in 36 (24.7%) patients after 37 (23.1%) CAS procedures. These patients had significantly longer intensive care unit and hospital stays than those who did not develop hypotension (p<0.001). PPH was associated with severe lesion calcification (OR 6.28, 95% CI 1.81 to 21.98, p=0.004) and contrast volume (OR 1.02, 95% CI 1.01 to 1.02, p<0.001). A 4-fold increase in the risk of PPH (OR 4.22, 95% CI 1.38 to 13.33, p=0.012) was found between the embolic protection device most associated with PPH (Angioguard) and the device least associated with PPH (Emboshield NAV6). A similar trend was also observed for the Precise vs Xact stents (OR 6, 95% CI 2.08 to 17.6, p=0.001). Bootstrapped multivariable modeling identified the Precise stent and contrast volume as significant predictors of persistent postprocedural hypotension. Further investigation of the contrast volume revealed associations with sex, severe calcification, arch type, previous coronary artery bypass surgery, and primary stenting, suggesting that the contrast volume reflects the complexity of the procedure. Conclusion: The complexity of the procedure and type of stent may play a role in the development of postprocedural hypotension after CAS.


  • Open Access

    First-in-man experience of self-expanding nitinol stents combined with drug-coated balloon in the treatment of femoropopliteal occlusive disease

    by Bibombe Patrice Mwipatayi, Kalpa Perera, Ali Daneshmand, Rhys Daniel, Jackie Wong, Shannon D Thomas, Sally A Burrows

    Purpose: The present study aimed to determine the safety and efficacy of a drug-coated balloon inflated within a thin-strut self-expanding bare-metal stent in patients with severe and complex femoropopliteal occlusive disease. Methods: This prospective study used the Pulsar-self-expanding stent and Passeo-18 Lux drug-coated balloon in patients with severe and complex femoropopliteal occlusive disease. The primary endpoint was the 12-month primary patency, and the secondary endpoints included 24-month primary patency, assisted primary patency, secondary patency, and clinically associated target lesion revascularisation. Results: The study included 44 patients (51 limbs). The mean age of the patients was 67.6 ± 10.2 years, with 73% men. Chronic limb severity was classified as Rutherford Category III in 41% of the patients, stage IV in 31%, and stage V in 27%. Lesions were predominantly Trans-Atlantic Inter-Society Consensus (TASC 2007) D (51%) and C (45%), with 32 (63%) chronic total occlusions. Procedural success was obtained in all cases. The mean lesion length was 200 ± 74.55 mm (95% CI = 167.09–208.01) with a mean number of stents per limb used of 1.57 ± 0.70 (95% CI = 1.37–1.76). Distal embolisation occurred in two patients. The primary patency rates at the 12- and 24-month follow-up were 94% (95% CI = 82.9–98.1) and 88% (95% CI = 75.7–94.5), respectively. The assisted primary was 94% (95% CI = 82.9–98.1) and secondary patency was 96% (95% CI = 85.2–99.0) at 24-month follow-up. The cumulative stent fracture rate at the 24-month follow-up was 10%. Freedom from clinically driven target lesion revascularisation was 94% (95% CI = 83–98%) at 12-month follow-up and 88% (95% CI = 76–94%) at 24-month follow-up, with two patients requiring a bypass graft. Conclusion: Our novel approach involving the combination of a thin-strut bare-metal stent and a drug-coated balloon may be safe and effective, with sustainable and promising clinical outcomes up to 24 months after treatment.


  • Open Access

    Delayed iliacus compartment syndrome following femoral artery puncture: case report and literature review

    by Bibombe P. Mwipatayi, Ali Daneshmand, Haider K. Bangash, Jackie Wong

    Iliacus compartment syndrome is a rare retroperitoneal compartment neuropathy caused by bleeding within the iliacus muscle leading to hematoma formation and compression upon the femoral nerve, causing both sensory and motor deficits. A 75-year-old Caucasian man presented with severe right hip pain associated with motor and sensory deficit in the right lower extremity, 2 weeks post elective balloon aortic valvuloplasty for critical aortic stenosis. A non-contrast computed tomography scan revealed low-attenuation areas in keeping with an iliacus hematoma. An iliacus fasciotomy and hematoma evacuation was performed with retroperitoneal approach. The patient reported marked reduction in his groin pain with clinical improvement of the right hip flexion though the sensory deficit was unchanged. On Day 3, postoperatively the patient died from respiratory and multi-organ failure. Iliac hematomas are rare and can be caused by traumatic and non-traumatic injury, and can be exacerbated by complications of anticoagulant therapy. Delaying surgical evacuation of the hematoma can lead to prolonged or permanent disability. However, there are other reports describing good recovery with non-operative management. Non-surgical intervention is recommended if radiological studies do not explicitly confirm the presence of a discreet hematoma compressing the femoral nerve, unless progression of symptoms increases.


  • Open Access

    Atypical leg ulcers after sclerotherapy for treatment of varicose veins: Case reports and literature review

    by Bibombe P. Mwipatayi, Catherine E. Western, Jackie Wong, Donna Angel

    Skin necrosis is a rare complication of foam sclerotherapy, a common form of treatment for varicose veins. Both patients presented to the outpatient clinic within 2-14days after foam sclerotherapy with Aethoxysklerol(®) 1%, with severe soft tissue and skin necrosis. Further aggressive treatment of the ulcer was required to resolve the necrosis, resulting in marked residual scar and well granulated leg ulcer respectively. Foam sclerotherapy is a common and usually well-tolerated treatment modality for varicose veins. The aetiology of skin necrosis is conventionally related to extravasation of sclerosant. In order to minimise the risk of necrosis, the lowest concentration and lowest volume of sclerosant necessary to achieve adequate treatment of the target vein should be used. We would like to emphasise that whilst skin and soft tissue necrosis is a rare complication of foam sclerotherapy, it is a complication that is highly disfiguring and requires aggressive treatment. As such, it should be adequately discussed with the patient prior to obtaining informed consent.


  • Endovascular Repair of Abdominal Aortic Aneurysms With Reverse Taper Neck Anatomy Using the Endurant Stent-Graft: Analysis of Stent-Graft Oversizing

    by Bibombe P. Mwipatayi, Alarick Picardo, Jackie Wong, Shannon D. Thomas, Vikram Vijayan

    Purpose To evaluate endovascular repair of infrarenal abdominal aortic aneurysms (AAA) using the Endurant stent-graft and compare the outcomes of patients with different neck anatomies, particularly as pertains to stent-graft oversizing. Methods A retrospective review was conducted of 75 consecutive patients (69 men; mean age 75 years) undergoing endovascular AAA repair using the Endurant Stent Graft System from December 2008 to September 2011. The mean AAA size was 57± 10 mm (range 51–92), with a mean proximal neck length of 33±10 mm (9–127) and a mean infrarenal neck angulation of 25°±15° (0°–91°). Patients were stratified according to neck anatomy [reverse taper (n=22) vs. inside (n=44) and outside (n=9) the Instructions for Use (IFU) criteria]. Standard safety and efficacy outcome measures were augmented by measurements of the percent oversizing at the proximal and distal neck and volumes of the proximal neck and stent-graft. Results Technical success was 100% in all groups, with no early or late type Ia endoleak detected in any group. Procedure time, contrast volumes, and radiation dosages were comparable in all groups. The reverse taper neck group had stent-graft diameters and volumes that were significantly larger (p=0.007) than the other groups. The proximal neck oversizing of the endograft was significantly greater (p=0.008) in the reverse taper neck group (42.9%± 17.5%) compared to the within the IFU group (30.1%± 11.7%). Over a mean follow-up of 20 months (range 14–46), there were no aneurysm-related deaths and 9 type II endoleaks (5 in the reverse taper neck group; overall, 3 were treated and 6 resolved spontaneously). The outside the IFU group suffered no endoleak of any type and had no secondary interventions. Conclusion The Endurant stent-graft can be utilized with acceptable results in more challenging neck anatomies, such as those with a reverse taper, as long as there is adequate oversizing of the stent-graft.